Cardiff Oncology has announced promising results from its Phase 2 trial evaluating onvansertib in combination with Zytiga (abiraterone) and prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The data, unveiled recently, indicate a significant improvement in radiographic progression-free survival (rPFS) compared to historical controls.
The trial's primary endpoint was radiographic progression-free survival (rPFS). The results showed a 50% reduction in radiographic progression or death, with a median rPFS of 9.2 months in the onvansertib arm. This compares favorably to the historical control rPFS of approximately 6 months typically observed with Zytiga and prednisone alone.
Study Design and Patient Population
The Phase 2 trial enrolled patients with mCRPC who had progressed on prior androgen deprivation therapy but were naive to Zytiga. Patients received onvansertib in combination with Zytiga and prednisone. The study aimed to assess the efficacy and safety of the combination therapy in this patient population.
Safety and Tolerability
According to the report, the combination of onvansertib, Zytiga, and prednisone was generally well-tolerated. The observed side effects were manageable, aligning with the known safety profiles of the individual drugs. Detailed safety data will be presented at an upcoming medical conference.
Implications for mCRPC Treatment
The current treatment landscape for mCRPC involves several options, including androgen receptor inhibitors, chemotherapy, and radiopharmaceuticals. However, resistance to these therapies often develops, highlighting the need for new treatment strategies. Onvansertib, a PLK1 inhibitor, represents a novel approach to targeting cancer cell proliferation. These findings suggest that onvansertib could potentially address this unmet need and improve outcomes for patients with mCRPC.
